A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Elderly Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Remission Induction Therapy
|Effective start/end date||8/11/15 → 2/28/19|
- ASTEX PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.